Bio Pharma Dive
SEPTEMBER 15, 2024
Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 15, 2024
(ImagesBazaar/Getty Images) A new study suggests staying on top of your eye health could offer a simple avenue for reducing your risks of future brain problems.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 15, 2024
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 15, 2024
The National Accreditation Board for Hospitals & Healthcare Providers (NABH) has unveiled a major update to its accreditation standards for hospitals, with the release of the 6th edition.
Pharmaceutical Technology
SEPTEMBER 15, 2024
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC treatment paradigm.
pharmaphorum
SEPTEMBER 15, 2024
Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona – showed that nearly two-thirds (61.6%) of patients with brain metastases at baseline who were treated with the HER2-directed antibody-drug conjugate (ADC) were alive without disease progression at one year.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
SEPTEMBER 15, 2024
GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class
Fierce Pharma
SEPTEMBER 15, 2024
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of chemotherapy. | Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate cancer with a combination free of chemotherapy.
FDA Law Blog
SEPTEMBER 15, 2024
By Kurt R. Karst — “Inter Partes Review” and “Section 101” are not terms you typically run into on this all-things-FDA blog, but we have talked about such patent-related issues before ( here and here ), and they are important legal (patent) principles, particularly in the context of drug and biological products (and the Hatch-Waxman Amendments and the Biologics Price Competition and Innovation Act (“BPCIA”)).
Cloudbyz
SEPTEMBER 15, 2024
Having a disaster recovery (DR) plan and business continuity plan (BCP) is critical for any eClinical systems and servers that manage clinical trials data. These systems handle vast amounts of sensitive and regulated information, and any disruptions or data loss can have severe consequences for patient safety, trial integrity, and regulatory compliance.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
JAMA Internal Medicine
SEPTEMBER 15, 2024
This case report describes a patient in their mid 70s who had an out-of-hospital cardiac arrest and was found to have irregular, narrow atrial fibrillation with rapid ventricular rhythm on electrocardiography imaging.
Expert insights. Personalized for you.
310 
Let's personalize your content